View Older Stories

Apr 30, 2026 12:01PM Kymera Therapeutics (KYMR) PT Lowered to $119 at Morgan Stanley

Apr 30, 2026 07:05AM Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c

Apr 13, 2026 05:52AM Bernstein on US Pharma and Biotech: Who might buy whom?

Apr 10, 2026 06:44AM H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)

Apr 9, 2026 07:03AM Gilead exercises option for Kymera's cancer drug candidate KT-200

Mar 30, 2026 04:21AM Kymera presents atopic dermatitis trial data at dermatology meeting

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 2, 2026 07:21AM Kymera Therapeutics (KYMR) PT Raised to $100 at Stephens

Feb 26, 2026 03:25PM Kymera Therapeutics (KYMR) PT Lowered to $123 at Morgan Stanley

Feb 26, 2026 11:56AM Kymera Therapeutics (KYMR) PT Raised to $108 at RBC Capital

Feb 26, 2026 11:56AM Kymera Therapeutics (KYMR) PT Raised to $108 at RBC Capital

Feb 26, 2026 10:53AM Stifel on Kymera Therapeutics (KYMR): 'pipeline progress remains an underappreciated long-term drive'

Feb 26, 2026 07:14AM Kymera Therapeutics (KYMR) Misses Q4 EPS by 18c

Feb 25, 2026 04:10PM Piper Sandler Assumes Kymera Therapeutics (KYMR) at Overweight

Jan 29, 2026 07:02AM Kymera begins dosing first patient in phase 2b asthma trial

Jan 13, 2026 07:01AM Kymera Therapeutics outlines 2026 clinical trial plans

Jan 6, 2026 05:35AM Wolfe Research Downgrades Kymera Therapeutics (KYMR) to Peerperform

Dec 16, 2025 05:15AM Kymera Therapeutics (KYMR) PT Raised to $103 at RBC Capital

Dec 11, 2025 07:33AM Kymera Therapeutics (KYMR) PT Raised to $110 at Stephens

Dec 11, 2025 04:43AM Kymera Therapeutics (KYMR) PT Raised to $120 at Mizuho

Dec 10, 2025 08:25AM Kymera Therapeutics (KYMR) PT Raised to $134 at H.C. Wainwright

Dec 9, 2025 02:27PM Kymera Therapeutics (KYMR) PT Raised to $122 at Jefferies

Dec 9, 2025 08:46AM Kymera Therapeutics (KYMR) PT Raised at Piper Sandler Following Positive BroADen Data

Dec 9, 2025 06:10AM Kymera Therapeutics (KYMR) PT Raised to $120 at Oppenheimer

Dec 9, 2025 05:33AM Kymera Therapeutics (KYMR) PT Raised to $116 at Wells Fargo

Dec 8, 2025 04:07PM Kymera Therapeutics (KYMR) PT Raised to $118 at Leerink Partners

Dec 8, 2025 04:01PM Kymera Therapeutics (KYMR) PT Raised to $127 at Morgan Stanley

Dec 8, 2025 04:00PM Kymera Therapeutics (KYMR) PT Raised to $138 at BTIG

Dec 8, 2025 09:56AM Kymera Therapeutics (KYMR) PT Raised to $114 at Stifel

Dec 8, 2025 06:59AM Kymera Therapeutics (KYMR) Halted, News Pending

Nov 26, 2025 08:55AM Kymera Therapeutics (KYMR) PT Raised to $80 at Truist Securities

Nov 25, 2025 07:01AM Kymera Therapeutics starts phase 2b atopic dermatitis trial

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 14, 2025 08:08AM Kymera Therapeutics' (KYMR) Ph2b AD Solidifying First-in-Class Position - Stifel

Nov 5, 2025 06:17AM Kymera Therapeutics (KYMR) PT Raised to $84 at H.C. Wainwright

Nov 4, 2025 01:19PM Kymera Therapeutics (KYMR) PT Raised to $67 at Oppenheimer

Nov 4, 2025 07:04AM Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c

Nov 3, 2025 02:33AM Guggenheim Assumes Kymera Therapeutics (KYMR) at Buy

Oct 27, 2025 07:00AM Kymera presents preclinical data for oral IRF5 degrader KT-579

Oct 24, 2025 05:27AM Citi Adds Kymera Therapeutics (KYMR) to 90-Day Upside Catalyst Watch

Oct 20, 2025 04:03PM Mizuho Starts Kymera Therapeutics (KYMR) at Outperform

Oct 7, 2025 09:01AM Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR)

Sep 30, 2025 04:29PM Kymera Therapeutics (KYMR) PT Raised to $63 at Oppenheimer

Sep 30, 2025 08:08AM Kymera Therapeutics (KYMR) PT Raised to $68 at Truist Securities

Sep 19, 2025 06:48AM Kymera Therapeutics (KYMR) PT Raised to $70 at H.C. Wainwright

Sep 17, 2025 04:35AM Barclays Starts Kymera Therapeutics (KYMR) at Overweight

Sep 16, 2025 02:30AM RBC Capital Starts Kymera Therapeutics (KYMR) at Outperform

Sep 11, 2025 05:39AM Kymera Therapeutics (KYMR) PT Raised to $88 at Wolfe Research

Aug 11, 2025 07:04AM Kymera Therapeutics (KYMR) Misses Q2 EPS by 12c

Jul 7, 2025 08:09AM Kymera Therapeutics (KYMR) PT Lowered to $65 at Brookline Capital Markets

View Older Stories